Shandong Xinhua Pharma Sustainability Profile
Shandong Xinhua Pharmaceutical Company Limited, commonly referred to as Xinhua Pharma, is a prominent player in the pharmaceutical industry, headquartered in Shandong, China. Established in 1996, the company has made significant strides in the development and production of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage forms. With a strong focus on research and development, Xinhua Pharma has carved out a niche in the production of high-quality generic medications and innovative therapies. The company is recognised for its commitment to quality and compliance with international standards, which has bolstered its market position both domestically and globally. Notable achievements include various certifications and partnerships that enhance its reputation as a reliable supplier in the pharmaceutical sector.
DitchCarbon Score
How does Shandong Xinhua Pharma's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shandong Xinhua Pharma's score of 25 is lower than 63% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shandong Xinhua Pharma's reported carbon emissions
In 2024, Shandong Xinhua Pharmaceutical Company Limited reported total carbon emissions of approximately 307,633,000 kg CO2e. This figure includes about 22,056,000 kg CO2e from Scope 1 emissions and around 285,577,000 kg CO2e from Scope 2 emissions. In comparison, the company’s total emissions for 2023 were about 260,643,000 kg CO2e, with Scope 1 emissions at approximately 18,956,000 kg CO2e and Scope 2 emissions at about 241,687,000 kg CO2e. Over the past few years, Shandong Xinhua Pharma has shown a slight increase in total emissions, rising from about 258,468,000 kg CO2e in 2022 and 250,960,000 kg CO2e in 2021. The company has not disclosed any Scope 3 emissions data, indicating a focus primarily on direct and indirect emissions from its operations. Currently, Shandong Xinhua Pharma has not set any specific reduction targets or initiatives, nor does it participate in recognised climate pledges such as the Science Based Targets initiative (SBTi). The absence of formal commitments suggests that the company may need to enhance its climate strategy to align with industry standards and expectations for sustainability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - |
How Carbon Intensive is Shandong Xinhua Pharma's Industry?
How Carbon Intensive is Shandong Xinhua Pharma's Location?
Shandong Xinhua Pharma's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shandong Xinhua Pharma has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
